login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
EDGEWISE THERAPEUTICS INC (EWTX) Stock News
USA
- NASDAQ:EWTX -
US28036F1057
-
Common Stock
15.62
USD
+0.92 (+6.26%)
Last: 10/15/2025, 4:30:02 PM
15.62
USD
0 (0%)
After Hours:
10/15/2025, 4:30:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
EWTX Latest News, Press Relases and Analysis
All
Press Releases
13 days ago - By: Edgewise Therapeutics
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
13 days ago - By: Edgewise Therapeutics
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society
a month ago - By: Edgewise Therapeutics
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
a month ago - By: Zacks Investment Research
Wall Street Analysts Believe Edgewise Therapeutics (EWTX) Could Rally 172.96%: Here's is How to Trade
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
2 months ago - By: Edgewise Therapeutics
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
2 months ago - By: Edgewise Therapeutics
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
3 months ago - By: Yahoo Finance
- Mentions:
PTON
UBS
STX
PNC
...
Peloton upgraded, Booking downgraded: Wall Street's top analyst calls
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
3 months ago - By: The Schall Law Firm
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
3 months ago - By: Yahoo Finance
Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
4 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
4 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
4 months ago - By: ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
4 months ago - By: Benzinga
- Mentions:
SBUX
CRCL
AYTU
SAIL
This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
4 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
4 months ago - By: Yahoo Finance
Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
4 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
4 months ago - By: ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
4 months ago - By: Benzinga
No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall
4 months ago - By: Edgewise Therapeutics
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies
4 months ago - By: Edgewise Therapeutics
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference
5 months ago - By: Zacks Investment Research
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
5 months ago - By: Zacks Investment Research
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
Please enable JavaScript to continue using this application.